Cholesterol represents an indispensable building block for human life, comprising nearly one-quarter of the solid substance in the brain and stabilizing red blood cell membranes [3]. Despite its physiological necessity for hormone synthesis, escalating levels of cholesterol serve as a primary risk factor for the development of cardiovascular diseases [3]. Plaque buildup, driven by excess cholesterol, constricts arterial pathways, leading to severe clinical outcomes such as angina, myocardial infarction, and stroke [3]. Understanding the distinction between low-density lipoprotein and high-density lipoprotein is critical for managing these risks [3]. The historical narrative of pharmaceutical innovation is defined by breakthrough medicines that have significantly extended human life expectancy [4]. Among these, Lipitor, or atorvastatin, stands out as one of the most successful interventions in medical history [6]. Discovered by Parke-Davis in the mid-1980s, the drug was a relative late